Compare Mutual Funds

Pros
3Y returns in the top 25% of the category.

3Y returns in the top 25% of the category.

Beats FD returns for both 3Y & 5Y duration.

Beats FD returns for both 3Y & 5Y duration.

Larger AUM within category.

Larger AUM within category.

Beats FD returns for both 3Y & 5Y duration.

Beats FD returns for both 3Y & 5Y duration.

Cons

-

5Y returns in the bottom 25% of the category.

5Y returns in the bottom 25% of the category.

3Y returns in the bottom 25% of the category.

3Y returns in the bottom 25% of the category.

INDMoney rank
4/10
10/10
Category

Equity, Sector - Healthcare

Equity, Sector - Healthcare

Fund Age

14 Years

14 Years

Fund AUM

₹1430 Cr

₹9166 Cr

Min Investment
  1. SIP ₹500
  2. Lumpsum ₹5000
  1. SIP ₹100
  2. Lumpsum ₹5000
Expense Ratio

1.34%

1%

Exit Load

1%

1%

Benchmark Index

BSE Healthcare TR INR

BSE Healthcare TR INR

No of Holdings

46

40

Top 5 Holdings
  1. Sun Pharmaceuticals Industries Ltd(7.62%)
  2. Divi's Laboratories Ltd(6.15%)
  3. Dr Reddy's Laboratories Ltd(5.24%)
  4. Ajanta Pharma Ltd(4.81%)
  5. Gland Pharma Ltd(4.06%)
  1. Sun Pharmaceuticals Industries Ltd(11.71%)
  2. Divi's Laboratories Ltd(7.1%)
  3. Lupin Ltd(6.17%)
  4. Cipla Ltd(6.01%)
  5. Dr Reddy's Laboratories Ltd(5.45%)
No of Sectors

1

1

Top 3 Sectors

Health

(100%)

Health

(100%)

Equity %

94.12%

97.3%

Debt %

-

-

P/E

38.71

37.98

P/B

5.38

5.6

Credit Quality

-

-

Modified Duration

-

-

YTM

-

-

1-Month Return

-1.26%

-0.76%

3-Month Return

-1.4%

-2.52%

6-Month Return

12.8%

7.84%

1-Year Return

13.46%

9.05%

3-Year Return

23.47%

18.56%

5-Year Return

16.24%

14.19%

Sharpe

1.03

0.83

Alpha

0.9

-2.19

Beta

0.96

0.89

Standard Deviation

16

14.87

Information Ratio

0.13

-1.14

Description

UTI Healthcare Fund is an equity fund.The fund could potentially beat inflation in the long-run.

Nippon India Pharma Fund is an equity fund.The fund could potentially beat inflation in the long-run.

Managers

Kamal Gada

Kinjal Desai, Amber Singhania, Sailesh Raj Bhan

Most Popular Comparisons